Every 424B that Biodexa Pharmaceuticals plc (BDRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BDRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDRX filings page.
Biodexa Pharmaceuticals PLC filed a prospectus supplement to its Form F-1 resale registration and incorporated a new Form 6-K. The update highlights European regulatory progress for its lead program.
The company announced EMA approval of a Clinical Trial Application for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis. The CTA permits sites in Denmark, Germany, the Netherlands, and Spain, with Italy expected to be added. The U.S. arm enrolled its first patient in mid-August 2025, and the first European patient is expected in 4Q 2025. The Serenta study is a randomized, double-blind, placebo-controlled registrational trial targeting 168 patients, randomized 2:1 to drug versus placebo. Management cited a $7 billion combined U.S.–Europe addressable market for FAP.
Biodexa’s ADS trade on Nasdaq under BDRX; the last reported closing price on October 31, 2025 was $6.49.